{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:10:40Z","timestamp":1789999840220,"version":"4.0.1"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01397","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:13:11Z","timestamp":1529539991000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["The US Military Commitment to Vaccine Development: A Century of Successes and Challenges"],"prefix":"10.3389","volume":"9","author":[{"given":"Silvia","family":"Ratto-Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Kyu","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20130426","DOI":"10.1098\/rstb.2013.0426","article-title":"After 2015: infectious diseases in a new era of health and development","volume":"369","author":"Dye","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B2","unstructured":"The Top 10 Causes of Death2017"},{"key":"B3","article-title":"General consideration of modes of transmission. Medical Department USA","volume-title":"Preventive Medicine in World War II: Communicable Diseases Transmitted Chiefly Through Respiratory and Alimentary Tracts","author":"Gordon","year":"1958"},{"key":"B4","first-page":"158","volume-title":"Protecting Our Forces: Improving Vaccine Acquisition and Availability in the U.S. Military","author":"Lemon","year":"2002"},{"key":"B5","volume-title":"The Evolution of Preventive Medicine in the United States Army, 1607\u20131939","author":"Stanhope","year":""},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/epirev\/mxj003","article-title":"Immunization to protect the US Armed Forces: heritage, current practice, and prospects","volume":"28","author":"Grabenstein","year":"2006","journal-title":"Epidemiol Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"D16","DOI":"10.1016\/j.vaccine.2009.07.044","article-title":"Vaccines for military use","volume":"27","author":"Artenstein","year":"2009","journal-title":"Vaccine"},{"key":"B8","unstructured":"The National Security Strategies of the United States of America2002"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1016\/j.vaccine.2013.07.082","article-title":"A model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU)","volume":"31","author":"Gibbons","year":"2013","journal-title":"Vaccine"},{"key":"B10","first-page":"33","article-title":"Smallpox and the American revolution","author":"Tschanz","year":"1995","journal-title":"Command: Military History, Strategy & Analysis"},{"key":"B11","volume-title":"Lackland Gets a Shot at Smallpox Vaccine for the First Time in a Decade, 14 Air Force Volunteers in San Antonio Are Inoculated Against a Disease the World Once Feared","author":"Christenson","year":"2003"},{"key":"B12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3201\/eid0504.990413","article-title":"Vaccines in civilian defense against bioterrorism","volume":"5","author":"Russell","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1586\/erv.11.46","article-title":"The strategic use of novel smallpox vaccines in the post-eradication world","volume":"10","author":"Golden","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.vaccine.2005.01.012","article-title":"The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program","volume":"23","author":"Poland","year":"2005","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1586\/14760584.7.8.1225","article-title":"Smallpox vaccines for biodefense: need and feasibility","volume":"7","author":"Artenstein","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"B16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.15585\/mmwr.mm6510a2","article-title":"Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses \u2013 recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015","volume":"65","author":"Petersen","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1086\/511869","article-title":"Yellow fever: epidemiology and prevention","volume":"44","author":"Barnett","year":"2007","journal-title":"Clin Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.1016\/j.vaccine.2007.07.030","article-title":"Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases","volume":"25","author":"Kitchen","year":"2007","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.15585\/mmwr.mm6617e2","article-title":"Addressing a yellow fever vaccine shortage \u2013 United States, 2016\u20132017","volume":"66","author":"Gershman","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1993","DOI":"10.1371\/journal.pone.0001993","article-title":"Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial","volume":"3","author":"Roukens","year":"2008","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710430","article-title":"Immunogenicity of fractional-dose vaccine during a yellow fever outbreak \u2013 preliminary report","author":"Ahuka-Mundeke","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/cid\/civ976","article-title":"Challenges and opportunities for typhoid fever control: a call for coordinated action","volume":"62","author":"Steele","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/clinids\/17.5.913","article-title":"A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery","volume":"17","author":"Watson","year":"1993","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S383","DOI":"10.1016\/j.amepre.2015.09.008","article-title":"Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines","volume":"49","author":"Pilishvili","year":"2015","journal-title":"Am J Prev Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S2213-2600(16)00052-7","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study","volume":"4","author":"Moore","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7205\/MILMED.170.4S.66","article-title":"History of U.S. military contributions to the study of respiratory infections","volume":"170","author":"Ottolini","year":"2005","journal-title":"Mil Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S456","DOI":"10.1093\/infdis\/136.Supplement_3.S456","article-title":"Antibody response of young adults to experimental influenza A\/New Jersey\/76 virus vaccines","volume":"136","author":"Meiklejohn","year":"1977","journal-title":"J Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/infdis\/138.5.618","article-title":"Antigenic drift and efficacy of influenza virus vaccines, 1976\u20131977","volume":"138","author":"Meiklejohn","year":"1978","journal-title":"J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/clinids\/1.6.946","article-title":"Comparison of several wild-type influenza viruses in the ferret tracheal organ culture system","volume":"1","author":"Hoke","year":"1979","journal-title":"Rev Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/infdis\/147.6.1099","article-title":"Efficacy of single-dose influenza in Air Force recruits","volume":"147","author":"Gremillion","year":"1983","journal-title":"J Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/cid\/ciu507","article-title":"Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines","volume":"59","author":"Radin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7205\/MILMED.170.4S.3","article-title":"History of U.S. military contributions to the study of vaccines against infectious diseases","volume":"170","author":"Artenstein","year":"2005","journal-title":"Mil Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1086\/505950","article-title":"The history of rubella and rubella vaccination leading to elimination","volume":"43","author":"Plotkin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"B35","first-page":"1","article-title":"Measles, mumps, and rubella \u2013 vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"47","author":"Watson","year":"1998","journal-title":"MMWR Recomm Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00508-008-1071-9","article-title":"Japanese encephalitis and vaccines: past and future prospects","volume":"120","author":"Paulke-Korinek","year":"2008","journal-title":"Wien Klin Wochenschr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1586\/14760584.2013.835638","article-title":"IXIARO updated: overview of clinical trials and developments with the inactivated vaccine against Japanese encephalitis","volume":"12","author":"Jelinek","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1586\/14760584.2015.1061939","article-title":"The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis","volume":"14","author":"Erra","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1586\/erv.10.139","article-title":"IMOJEV((R)): a yellow fever virus-based novel Japanese encephalitis vaccine","volume":"9","author":"Appaiahgari","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1084\/jem.129.6.1367","article-title":"Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1084\/jem.129.6.1385","article-title":"Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.4161\/hv.24689","article-title":"Meningococcal group B vaccines","volume":"9","author":"Findlow","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.patbio.2015.04.003","article-title":"Meningococcal vaccines: current state and future outlook","volume":"63","author":"Leca","year":"2015","journal-title":"Pathol Biol (Paris)"},{"key":"B46","volume-title":"The Fever Trail: In Search of the Cure for Malaria","author":"Honigsbaum","year":"2002"},{"key":"B47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7205\/MILMED.170.4S.12","article-title":"History of U.S. military contributions to the study of malaria","volume":"170","author":"Ockenhouse","year":"2005","journal-title":"Mil Med"},{"key":"B48","volume-title":"The Malaria Project","author":"Masterson","year":"2014"},{"key":"B49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4269\/ajtmh.1961.10.317","article-title":"Chloroquine resistance in Plasmodium falciparum","volume":"10","author":"Young","year":"1961","journal-title":"Am J Trop Med Hyg"},{"key":"B50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.7326\/0003-4819-70-1-150","article-title":"The army malaria research program","volume":"70","author":"Tigertt","year":"1969","journal-title":"Ann Intern Med"},{"key":"B51","first-page":"13","article-title":"Human immunization with attenuated sporozoites","volume":"68","author":"Rieckmann","year":"1990","journal-title":"Bull World Health Organ"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/339409","article-title":"Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites","volume":"185","author":"Hoffman","year":"2002","journal-title":"J Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder","year":"2013","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka","year":"2016","journal-title":"Nat Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"S319","DOI":"10.1016\/j.amepre.2015.09.011","article-title":"The March toward malaria vaccines","volume":"49","author":"Hoffman","year":"2015","journal-title":"Am J Prev Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/302536a0","article-title":"Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi","volume":"302","author":"Ellis","year":"1983","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJM198609043151001","article-title":"Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum","volume":"315","author":"Hoffman","year":"1986","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1073\/pnas.85.4.1199","article-title":"Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule","volume":"85","author":"Good","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B60","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Rts","year":"2011","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Rts","year":"2012","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","article-title":"Four-year efficacy of RTS,S\/AS01E and its interaction with malaria exposure","volume":"368","author":"Olotu","year":"2013","journal-title":"N Engl J Med"},{"key":"B65","first-page":"33","volume-title":"Malaria vaccine: WHO position paper 2016. Weekly Epidemiological Record","year":"2016"},{"key":"B66","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMcp0803572","article-title":"Clinical practice. Malaria prevention in short-term travelers","volume":"359","author":"Freedman","year":"2008","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study","volume":"214","author":"Regules","year":"2016","journal-title":"J Infect Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.vaccine.2015.12.074","article-title":"Status of vaccine research and development of vaccines for malaria","volume":"34","author":"Birkett","year":"2016","journal-title":"Vaccine"},{"key":"B69","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3201\/eid1804.110134","article-title":"Dengue and US military operations from the Spanish-American War through today","volume":"18","author":"Gibbons","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1073\/pnas.91.7.2395","article-title":"Dengue: the risk to developed and developing countries","volume":"91","author":"Monath","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B71","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.1016\/j.vaccine.2015.09.103","article-title":"Recent advances in dengue pathogenesis and clinical management","volume":"33","author":"Simmons","year":"2015","journal-title":"Vaccine"},{"key":"B72","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/01.qco.0000433310.28771.cc","article-title":"Current issues in dengue vaccination","volume":"26","author":"Thomas","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"674","DOI":"10.4161\/hv.7.6.14985","article-title":"Vaccines for the prevention of dengue: development update","volume":"7","author":"Thomas","year":"2011","journal-title":"Hum Vaccin"},{"key":"B74","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"B78","first-page":"349","volume-title":"Dengue vaccine: WHO position paper 2016. Weekly Epidemiological Record","year":"2016"},{"key":"B79","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4269\/ajtmh.14-0625","article-title":"A phase II, randomized, safety and immunogenicity trial of a re-derived, live-attenuated dengue virus vaccine in healthy children and adults living in Puerto Rico","volume":"93","author":"Bauer","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4269\/ajtmh.17-0627","article-title":"Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico","volume":"98","author":"Diaz","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B82","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B83","doi-asserted-by":"publisher","first-page":"42","DOI":"10.7205\/MILMED-D-10-00168","article-title":"U.S. Military HIV Research Program: successfully integrating HIV vaccine research with prevention, care, and treatment","volume":"175","author":"Reilly","year":"2010","journal-title":"Mil Med"},{"key":"B84","doi-asserted-by":"crossref","first-page":"588","DOI":"10.7205\/MILMED.169.8.588","article-title":"Foundations for a phase III human immunodeficiency virus vaccine trial: a decade of Thai-U.S. Army collaborative research","volume":"169","author":"Brown","year":"2004","journal-title":"Mil Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1089\/08892220260387986","article-title":"Heterosexually acquired CRF01_AE\/B recombinant HIV type 1 found in Thailand","volume":"18","author":"Viputtijul","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/00002030-199509000-00012","article-title":"Declining prevalence of HIV-1 infection in young Thai men","volume":"9","author":"Mason","year":"1995","journal-title":"AIDS"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S0264-410X(99)00421-1","article-title":"A phase I\/II trial of HIV SF2 gp120\/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences","volume":"18","author":"Nitayaphan","year":"2000","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1086\/376506","article-title":"Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults","volume":"188","author":"Pitisuttithum","year":"2003","journal-title":"J Infect Dis"},{"key":"B89","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1086\/314895","article-title":"A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers","volume":"180","author":"Evans","year":"1999","journal-title":"J Infect Dis"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1086\/319863","article-title":"Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers","volume":"183","author":"Belshe","year":"2001","journal-title":"J Infect Dis"},{"key":"B91","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00042560-200203010-00005","article-title":"Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A","volume":"29","author":"Gupta","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B92","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1086\/422258","article-title":"Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults","volume":"190","author":"Nitayaphan","year":"2004","journal-title":"J Infect Dis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/QAI.0b013e3181354bd7","article-title":"A phase 1\/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023\/LAI-DID) or bivalent gp120 (CM235\/SF2) boost","volume":"46","author":"Thongcharoen","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e13983","DOI":"10.1371\/journal.pone.0013983","article-title":"Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate","volume":"5","author":"Currier","year":"2010","journal-title":"PLoS One"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/infdis\/jix456","article-title":"Safety and immunogenicity of PENNVAX-G DNA prime administered by biojector 2000 or CELLECTRA electroporation device with modified vaccinia ankara-CMDR boost","volume":"216","author":"Ake","year":"2017","journal-title":"J Infect Dis"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/imr.12514","article-title":"Complex immune correlates of protection in HIV-1 vaccine efficacy trials","volume":"275","author":"Tomaras","year":"2017","journal-title":"Immunol Rev"},{"key":"B99","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1086\/427501","article-title":"Gastroenteritis in US marines during operation Iraqi freedom","volume":"40","author":"Thornton","year":"2005","journal-title":"Clin Infect Dis"},{"key":"B100","first-page":"10","article-title":"An outbreak of Campylobacter enteritis associated with a community water supply on a U.S. military installation","volume":"21","author":"DeFraites","year":"2014","journal-title":"MSMR"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.vaccine.2008.03.008","article-title":"Development of a travelers\u2019 diarrhea vaccine for the military: how much is an ounce of prevention really worth?","volume":"26","author":"Riddle","year":"2008","journal-title":"Vaccine"},{"key":"B102","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1016\/j.vaccine.2014.07.070","article-title":"Relative cost-effectiveness of a norovirus vaccine in the deployed military setting compared to a vaccine against Campylobacter sp., ETEC, and Shigella sp","volume":"32","author":"Tallant","year":"2014","journal-title":"Vaccine"},{"key":"B103","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.vaccine.2014.11.049","article-title":"An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children","volume":"33","author":"Walker","year":"2015","journal-title":"Vaccine"},{"key":"B104","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1086\/339908","article-title":"The past and present threat of rickettsial diseases to military medicine and international public health","volume":"34","author":"Kelly","year":"2002","journal-title":"Clin Infect Dis"},{"key":"B105","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1016\/j.vaccine.2012.08.025","article-title":"US Military contributions to the global response to pandemic chikungunya","volume":"30","author":"Hoke","year":"2012","journal-title":"Vaccine"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.vaccine.2016.03.076","article-title":"Status of research and development of vaccines for chikungunya","volume":"34","author":"Smalley","year":"2016","journal-title":"Vaccine"},{"key":"B107","doi-asserted-by":"publisher","first-page":"S857","DOI":"10.1093\/infdis\/jix383","article-title":"Pandemic Zika: a formidable challenge to medicine and public health","volume":"216","author":"Morens","year":"2017","journal-title":"J Infect Dis"},{"key":"B108","doi-asserted-by":"publisher","first-page":"S860","DOI":"10.1093\/infdis\/jix451","article-title":"History and emergence of Zika virus","volume":"216","author":"Gubler","year":"2017","journal-title":"J Infect Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"S957","DOI":"10.1093\/infdis\/jix464","article-title":"Zika virus vaccine development","volume":"216","author":"Morabito","year":"2017","journal-title":"J Infect Dis"},{"key":"B110","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.aag0219","article-title":"Epidemiology. Countering the Zika epidemic in Latin America","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science"},{"key":"B111","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/erv.12.15","article-title":"Vaccines for hantaviruses: progress and issues","volume":"11","author":"Schmaljohn","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"B112","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/(SICI)1096-9071(200001)60:1<77::AID-JMV13>3.0.CO;2-S","article-title":"Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine","volume":"60","author":"McClain","year":"2000","journal-title":"J Med Virol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/j.vaccine.2012.01.024","article-title":"A phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome","volume":"30","author":"Boudreau","year":"2012","journal-title":"Vaccine"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.4161\/hv.20503","article-title":"Military vaccines in today\u2019s environment","volume":"8","author":"Schmaljohn","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B115","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1080\/08998280.2004.11928002","article-title":"Biological warfare and bioterrorism: a historical review","volume":"17","author":"Riedel","year":"2004","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B116","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1517\/14712598.2.8.883","article-title":"Vaccines for category A bioterrorism diseases","volume":"2","author":"Lutwick","year":"2002","journal-title":"Expert Opin Biol Ther"},{"key":"B117","first-page":"S56","article-title":"Vaccines and bioterrorism: smallpox and anthrax","volume":"52","author":"Kimmel","year":"2003","journal-title":"J Fam Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:13:22Z","timestamp":1529540002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":117,"alternative-id":["10.3389\/fimmu.2018.01397"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01397","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"article-number":"1397"}}